IASO Biotherapeutics
IASO Biotherapeutics is a cell-therapy company based in Nanjing and Shanghai. Its BCMA CAR-T therapy equecabtagene autoleucel (eque-cel, FUCASO) is approved in mainland China, Singapore and Hong Kong, and it presented first-in-human data for the in vivo CAR-T IASO206 in 2026.
| Headquarters | Nanjing; Shanghai, China |
|---|---|
| Listing | Not disclosed |
| Lead asset / stage | equecabtagene autoleucel (eque-cel; FUCASO) Approved — China; Singapore; Hong Kong |
| Latest event | IASO presented first-in-human data for BCMA-targeted in vivo CAR-T product IASO206 at IMS 2026. |